The metabolomics side of frailty: Toward personalized medicine for the aged

Anna Picca, Hélio José Coelho-Junior, Matteo Cesari, Federico Marini, Alfredo Miccheli, Jacopo Gervasoni, Maurizio Bossola, Francesco Landi, Roberto Bernabei, Emanuele Marzetti, Riccardo Calvani

Research output: Contribution to journalReview article

Abstract

Frailty encompasses several domains (i.e., metabolic, physical, cognitive). The multisystem derangements underlying frailty pathophysiology, its phenotypic heterogeneity, and the fluctuations of individuals across severity states have hampered a comprehensive appraisal of the condition. Circulating biomarkers emerged as an alleged tool for capturing this complexity and, as proxies for organismal metabolic changes, may hold the advantages of: 1) supporting diagnosis, 2) tracking the progression, 3) assisting healthcare professionals in clinical and therapeutic decision-making, and 4) verifying the efficacy of an intervention before measurable clinical manifestations occur. Among available analytical tools, metabolomics are able to identify and quantify the (ideally) whole repertoire of small molecules in biological matrices (i.e., cells, tissues, and biological fluids). Results of metabolomics analysis may define the final output of genome-environment interactions at the individual level. This entire collection of metabolites is called “metabolome” and is highly dynamic. Here, we discuss how monitoring the dynamics of metabolic profiles may provide a read-out of the environmental and clinical disturbances affecting cell homeostasis in frailty-associated conditions.

Original languageEnglish
Article number110692
JournalExperimental Gerontology
Volume126
DOIs
Publication statusPublished - Oct 15 2019

Fingerprint

Precision Medicine
Metabolomics
Metabolome
Medicine
Proxy
Biomarkers
Metabolites
Homeostasis
Genes
Decision making
Genome
Tissue
Delivery of Health Care
Molecules
Fluids
Monitoring
Therapeutics
Clinical Decision-Making

Keywords

  • Biomarkers
  • Endophenotype
  • Metabotype
  • Multivariate analysis
  • Omics
  • Person-tailored

ASJC Scopus subject areas

  • Biochemistry
  • Ageing
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology

Cite this

The metabolomics side of frailty : Toward personalized medicine for the aged. / Picca, Anna; Coelho-Junior, Hélio José; Cesari, Matteo; Marini, Federico; Miccheli, Alfredo; Gervasoni, Jacopo; Bossola, Maurizio; Landi, Francesco; Bernabei, Roberto; Marzetti, Emanuele; Calvani, Riccardo.

In: Experimental Gerontology, Vol. 126, 110692, 15.10.2019.

Research output: Contribution to journalReview article

@article{3a1a6c0faba4433d90d74618a285b7d4,
title = "The metabolomics side of frailty: Toward personalized medicine for the aged",
abstract = "Frailty encompasses several domains (i.e., metabolic, physical, cognitive). The multisystem derangements underlying frailty pathophysiology, its phenotypic heterogeneity, and the fluctuations of individuals across severity states have hampered a comprehensive appraisal of the condition. Circulating biomarkers emerged as an alleged tool for capturing this complexity and, as proxies for organismal metabolic changes, may hold the advantages of: 1) supporting diagnosis, 2) tracking the progression, 3) assisting healthcare professionals in clinical and therapeutic decision-making, and 4) verifying the efficacy of an intervention before measurable clinical manifestations occur. Among available analytical tools, metabolomics are able to identify and quantify the (ideally) whole repertoire of small molecules in biological matrices (i.e., cells, tissues, and biological fluids). Results of metabolomics analysis may define the final output of genome-environment interactions at the individual level. This entire collection of metabolites is called “metabolome” and is highly dynamic. Here, we discuss how monitoring the dynamics of metabolic profiles may provide a read-out of the environmental and clinical disturbances affecting cell homeostasis in frailty-associated conditions.",
keywords = "Biomarkers, Endophenotype, Metabotype, Multivariate analysis, Omics, Person-tailored",
author = "Anna Picca and Coelho-Junior, {H{\'e}lio Jos{\'e}} and Matteo Cesari and Federico Marini and Alfredo Miccheli and Jacopo Gervasoni and Maurizio Bossola and Francesco Landi and Roberto Bernabei and Emanuele Marzetti and Riccardo Calvani",
year = "2019",
month = "10",
day = "15",
doi = "10.1016/j.exger.2019.110692",
language = "English",
volume = "126",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The metabolomics side of frailty

T2 - Toward personalized medicine for the aged

AU - Picca, Anna

AU - Coelho-Junior, Hélio José

AU - Cesari, Matteo

AU - Marini, Federico

AU - Miccheli, Alfredo

AU - Gervasoni, Jacopo

AU - Bossola, Maurizio

AU - Landi, Francesco

AU - Bernabei, Roberto

AU - Marzetti, Emanuele

AU - Calvani, Riccardo

PY - 2019/10/15

Y1 - 2019/10/15

N2 - Frailty encompasses several domains (i.e., metabolic, physical, cognitive). The multisystem derangements underlying frailty pathophysiology, its phenotypic heterogeneity, and the fluctuations of individuals across severity states have hampered a comprehensive appraisal of the condition. Circulating biomarkers emerged as an alleged tool for capturing this complexity and, as proxies for organismal metabolic changes, may hold the advantages of: 1) supporting diagnosis, 2) tracking the progression, 3) assisting healthcare professionals in clinical and therapeutic decision-making, and 4) verifying the efficacy of an intervention before measurable clinical manifestations occur. Among available analytical tools, metabolomics are able to identify and quantify the (ideally) whole repertoire of small molecules in biological matrices (i.e., cells, tissues, and biological fluids). Results of metabolomics analysis may define the final output of genome-environment interactions at the individual level. This entire collection of metabolites is called “metabolome” and is highly dynamic. Here, we discuss how monitoring the dynamics of metabolic profiles may provide a read-out of the environmental and clinical disturbances affecting cell homeostasis in frailty-associated conditions.

AB - Frailty encompasses several domains (i.e., metabolic, physical, cognitive). The multisystem derangements underlying frailty pathophysiology, its phenotypic heterogeneity, and the fluctuations of individuals across severity states have hampered a comprehensive appraisal of the condition. Circulating biomarkers emerged as an alleged tool for capturing this complexity and, as proxies for organismal metabolic changes, may hold the advantages of: 1) supporting diagnosis, 2) tracking the progression, 3) assisting healthcare professionals in clinical and therapeutic decision-making, and 4) verifying the efficacy of an intervention before measurable clinical manifestations occur. Among available analytical tools, metabolomics are able to identify and quantify the (ideally) whole repertoire of small molecules in biological matrices (i.e., cells, tissues, and biological fluids). Results of metabolomics analysis may define the final output of genome-environment interactions at the individual level. This entire collection of metabolites is called “metabolome” and is highly dynamic. Here, we discuss how monitoring the dynamics of metabolic profiles may provide a read-out of the environmental and clinical disturbances affecting cell homeostasis in frailty-associated conditions.

KW - Biomarkers

KW - Endophenotype

KW - Metabotype

KW - Multivariate analysis

KW - Omics

KW - Person-tailored

UR - http://www.scopus.com/inward/record.url?scp=85070927393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070927393&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2019.110692

DO - 10.1016/j.exger.2019.110692

M3 - Review article

AN - SCOPUS:85070927393

VL - 126

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

M1 - 110692

ER -